Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.
BioLineRx Ltd. (BLRX) generates frequent news flow as a biopharmaceutical company focused on oncology and rare diseases. Its updates cover the performance of its approved product APHEXDA (motixafortide), progress in clinical trials, and developments in its partnerships and joint ventures.
News about BioLineRx often highlights APHEXDA’s commercial performance in stem cell mobilization for autologous transplantation in multiple myeloma, including royalty revenues from Ayrmid Ltd. and Gloria Biosciences. Investors and observers can follow how APHEXDA sales contribute to BioLineRx’s reported revenues and how the company manages its operating expenses and cash runway.
A significant portion of BLRX news relates to clinical development milestones. This includes data from the CheMo4METPANC Phase 2b trial of motixafortide in metastatic pancreatic cancer, such as pilot‑phase outcomes and biomarker analyses, as well as updates on Phase 1 studies of motixafortide for CD34+ hematopoietic stem cell mobilization in gene therapies for sickle cell disease. Company announcements also describe conference presentations at major oncology meetings.
Another key news theme is the GLIX1 joint venture with Hemispherian AS. Releases describe the structure of the joint venture, IND clearance for a Phase 1/2a glioblastoma study, Orphan Drug Designation, and intellectual property milestones, including a U.S. Patent and Trademark Office Notice of Allowance for a patent covering GLIX1 in cancers where cytidine deaminase is not over‑expressed.
Visitors to this BLRX news page can review press releases on quarterly and annual financial results, corporate updates, shareholder meeting outcomes, and regulatory filings referenced in Form 6‑K reports. For anyone tracking BioLineRx’s pipeline evolution, partnerships and financial position, this consolidated news feed offers a structured view of the company’s ongoing activities.
BioLineRx Ltd. (NASDAQ: BLRX) announced positive results from an interim analysis of the ongoing GENESIS Phase 3 trial for motixafortide, which targets stem cell mobilization in multiple myeloma patients. The independent Data Monitoring Committee recommended halting patient enrollment after identifying statistically significant evidence favoring motixafortide treatment, concluding at 122 patients instead of the planned 177. The final results are expected in 2021, aiming to establish motixafortide as the new standard of care alongside G-CSF.
BioLineRx Ltd. (NASDAQ: BLRX) announced the initiation of a Phase 2 clinical trial for Motixafortide, a CXCR4-inhibitor, in combination with cemiplimab and standard chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The study, led by Columbia University, aims to enroll 40 patients, assessing overall response rate (ORR) and other secondary outcomes. Data is expected in mid-2022. This approach targets a significant unmet need in pancreatic cancer treatment, given the low response rates of current therapies.
BioLineRx Ltd. (NASDAQ: BLRX) announced that approximately 65% of patients have been enrolled in the GENESIS Phase 3 trial for motixafortide (BL-8040) aimed at mobilizing hematopoietic stem cells for multiple myeloma autologous transplantation. An interim efficacy analysis is scheduled for the second half of 2020. Depending on results, recruitment may cease if the primary endpoint is met. The trial has seen a lower-than-anticipated patient dropout rate. Results are expected in early 2021, maintaining blinding post-transplantation.
BioLineRx Ltd. (NASDAQ: BLRX) announced its financial results for Q2 2020, showing a net loss of $6.8 million compared to $5.5 million in Q2 2019. Despite a decrease in research and development expenses by 12.5%, total operating loss stood at $5.6 million. The company raised $13.4 million in gross proceeds from direct offerings, strengthening its balance sheet. Upcoming milestones include three key data readouts in clinical trials for pancreatic cancer and stem cell mobilization expected by year-end.
BioLineRx Ltd. (NASDAQ: BLRX) will announce its unaudited financial results for the quarter ending June 30, 2020, on August 6, 2020, before US markets open. A conference call featuring CEO Philip Serlin will occur the same day at 10:00 a.m. EDT. Investors can dial in or access the call via a webcast on the company's Investor Relations page. The conference call replay will be available for two hours post-live and through August 8, 2020, via designated dial-ins.